McKesson Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Assessing McKesson (MCK) Valuation After Fiscal 2026 Earnings And Sector Volatility

AI-generated analysis

πŸ“Š McKesson reported full-year fiscal 2026 results with US$403.43 billion in sales and US$4.76 billion in net income.

πŸ“‰ Despite strong earnings, the stock price has declined over the last month (11.89%) and quarter (20.44%).

πŸ€– Long-term performance remains robust with a 5-year total shareholder return of 296.55%.

πŸ’° Analyst fair value targets at $990.87 suggest the current price of $754.76 may be undervalued.

πŸ”¬ The company is positioned to gain market share as pharmaceutical supply chains grow more complex.

⚠️ Potential risks include tighter drug pricing regulations and vertical integration by manufacturers or payers.

πŸ“ˆ The stock trades at a P/E of 21.3x, which is above peer averages but below analyst fair ratio estimates.

βš–οΈ Valuation signals are mixed as the stock appears cheaper than the broader healthcare sector but pricier than peers.

🧐 Investors face a dilemma regarding whether to prioritize the peer premium or the gap to the fair value ratio.

🌟 The analysis suggests McKesson could be temporarily out of favor and presents potential upside opportunities.

πŸ›‘οΈ Diversification is recommended through high-quality undervalued stocks, dividend aristocrats, and resilient low-risk companies.

⚠️ This analysis relies on historical data and forecasts and does not constitute financial advice.

Bullish Signals
  • McKesson reported strong full-year results for the period ended March 31, 2026, with sales reaching US$403.43b and net income of US$4.76b.
  • The company demonstrated higher earnings per year-over-year growth alongside improved margins and top-line expansion.
  • Despite recent short-term volatility, the 5-year total shareholder return stands at an impressive 296.55%, highlighting strong long-term performance.
  • Analyst fair value calculations peg McKesson at $990.87, suggesting the stock is currently significantly undervalued compared to its last close of $754.76.
  • The business model benefits from increasing complexity in the pharmaceutical supply chain, which disproportionately favors large distributors like McKesson for competitive market share gains.
  • Current P/E multiple of 21.3x is slightly below the fair ratio estimate of 29.4x, indicating potential upside if sentiment corrects.
Risk Factors
  • McKesson's share price has declined significantly recently, with a 30-day decline of 11.89% and a 90-day decline of 20.44%, indicating immediate market pressure despite positive earnings.
  • The current stock price of $754.76 trades below analyst price targets, suggesting the market may already be incorporating near-term risks that contradict the bullish valuation narrative.
  • Regulatory concerns pose a threat to McKesson's profit margins if stricter drug pricing regulations are enacted in the coming years.
  • Competitive threats exist as vertical integration by manufacturers and payers could sideline traditional distributors like McKesson, potentially eroding its market share.
  • The stock trades at a P/E of 21.3x, which appears more expensive than its closest peers at 20.4x, creating less room for error if market sentiment turns negative.
  • While the fair value estimate of $990.87 suggests undervaluation, the divergence between this long-term target and current peer-relative pricing creates mixed signals on value.
  • The article notes that the analyst narrative relies on future cash flows assuming the business looks very different to today, introducing uncertainty if those transformative conditions do not materialize.
Full Analysis
McKesson (MCK) recently reported full-year fiscal 2026 results ending March 31, 2026, showing sales of US$403.43 billion and net income of US$4.76 billion, accompanied by higher earnings per share. Despite these solid operational results and a five-year total shareholder return of 296.55%, the stock has experienced recent weakness, falling 20.44% over 90 days and trading below analyst price targets with a one-day gain of only 1.49%. The article highlights a discrepancy between market sentiment and valuation models, where Simply Wall St's analysis pegs a fair value of $990.87 against the last closing price of $754.76, labeling the stock as undervalued based on future cash flows and projected revenue expansion. The bullish narrative driving this higher fair value assumes McKesson will benefit from increasing supply chain complexity, including demands for biosimilars management, cold chain logistics, and personalized medicine, which favors large distributors over smaller competitors. This structural advantage is expected to drive top-line growth and margin expansion. However, the valuation relies on specific assumptions that could be tested by tighter drug pricing regulations or increased vertical integration by pharmaceutical manufacturers and payers, which might sideline traditional distribution models. Financial metrics present a mixed picture regarding relative value; while McKesson trades at a forward P/E ratio of 21.3x, which is slightly above peer averages of 20.4x but below the analyst fair ratio estimate of 29.4x, this creates conflicting signals for investors. The stock appears as good value when compared to the broader US healthcare industry but looks more expensive than its closest peers, potentially leaving less room for error if market sentiment deteriorates. Consequently, investors must decide whether the long-term growth narrative justifies a premium over peer averages or if the current pullback represents a buying opportunity where the market is already pricing in future risks.